Insight Holdings Group, LLC and its affiliated entities, which hold a ten percent stake in Hinge Health, Inc. (NASDAQ:HNGE), reported a series of stock transactions, including significant sales, over three days in June.
The entities collectively sold 727,793 shares of Hinge Health Class A Common Stock for a total value of approximately $51.6 million. These sales occurred between June 22 and June 24, 2026, at weighted average prices ranging from $70.2145 to $71.6669 per share. According to footnotes in the filing, the individual transaction prices for these sales ranged from $70.000 to $72.075 per share.
The timing of these sales is notable, as the stock is currently trading at $70.56, just 1% below its 52-week high of $72.39, following a remarkable 58% gain over the past year. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value, which may have influenced the insider’s decision to reduce holdings. Investors can access the complete valuation analysis and 10 additional InvestingPro Tips to better understand HNGE’s investment potential.
Prior to these sales, Insight Holdings Group and its affiliates converted a total of 870,104 shares of Class B Common Stock into Class A Common Stock. These conversions took place on June 22, 23, and 24, 2026, with each Class B share converting into one Class A share at the option of the holder.
The filing indicates that Insight Holdings Group, LLC acts as the sole shareholder of Insight Venture Associates X, Ltd., which is the general partner for several Insight Venture Partners funds that directly hold the shares. All reported transactions were conducted under a Rule 10b5-1 trading plan, adopted on August 20, 2025. The reporting person has undertaken to provide full information regarding the number of shares sold at each separate price within the stated ranges upon request.
In other recent news, Hinge Health Inc has been the focus of several analyst updates following its Investor Day and Movement client conference. Canaccord raised its price target for Hinge Health to $76, maintaining a Buy rating, citing the company’s expectation to add 4 to 5 million covered lives during the 2026 selling season. KeyBanc also increased its price target to $90, highlighting new product offerings, including a surgical option through HingeSelect, announced at the investor event. Citizens reaffirmed its Market Outperform rating with an $80 price target after attending the company’s Movement conference. Truist Securities raised its target to $85, expressing confidence in Hinge Health’s growth trajectory. Stifel reiterated a Buy rating with a $79 price target, noting the company’s surgical expansion and revised financial targets. These developments reflect a positive outlook from multiple analysts on Hinge Health’s future prospects.